These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2543263)

  • 1. An immunohistochemical investigation of the human neostriatum in Huntington's disease.
    Goto S; Hirano A; Rojas-Corona RR
    Ann Neurol; 1989 Mar; 25(3):298-304. PubMed ID: 2543263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons.
    Cicchetti F; Parent A
    Mov Disord; 1996 Nov; 11(6):619-26. PubMed ID: 8914086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A morphometric reevaluation of Huntington's chorea with special reference to the large neurons in the neostriatum.
    Oyanagi K; Ikuta F
    Clin Neuropathol; 1987; 6(2):71-9. PubMed ID: 2954733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease human brain.
    Curtis MA; Penney EB; Pearson J; Dragunow M; Connor B; Faull RL
    Neuroscience; 2005; 132(3):777-88. PubMed ID: 15837138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
    Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
    Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fate of the large striatal interneurons expressing calretinin in Huntington's disease.
    Massouh M; Wallman MJ; Pourcher E; Parent A
    Neurosci Res; 2008 Dec; 62(4):216-24. PubMed ID: 18801393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study.
    Albin RL; Qin Y; Young AB; Penney JB; Chesselet MF
    Ann Neurol; 1991 Oct; 30(4):542-9. PubMed ID: 1838677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.
    Augood SJ; Faull RL; Emson PC
    Ann Neurol; 1997 Aug; 42(2):215-21. PubMed ID: 9266732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients.
    Richfield EK; Maguire-Zeiss KA; Vonkeman HE; Voorn P
    Ann Neurol; 1995 Dec; 38(6):852-61. PubMed ID: 8526457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.
    Peinemann A; Schuller S; Pohl C; Jahn T; Weindl A; Kassubek J
    J Neurol Sci; 2005 Dec; 239(1):11-9. PubMed ID: 16185716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.
    Richfield EK; Herkenham M
    Ann Neurol; 1994 Oct; 36(4):577-84. PubMed ID: 7944290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
    Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
    Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus.
    Ma L; Nicholson LF
    Brain Res; 2004 Aug; 1018(1):10-7. PubMed ID: 15262199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
    Goto S; Hirano A; Rojas-Corona RR
    Acta Neuropathol; 1989; 78(5):543-50. PubMed ID: 2479214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament and neural cell adhesion molecule immunocytochemistry of Huntington's disease striatum.
    Nihei K; Kowall NW
    Ann Neurol; 1992 Jan; 31(1):59-63. PubMed ID: 1531909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptophysin expression in the striatum in Huntington's disease.
    Goto S; Hirano A
    Acta Neuropathol; 1990; 80(1):88-91. PubMed ID: 2141751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration.
    Goto S; Hirano A; Matsumoto S
    Ann Neurol; 1989 Dec; 26(6):766-70. PubMed ID: 2557795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
    Weeks RA; Piccini P; Harding AE; Brooks DJ
    Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.